(Total Views: 368)
Posted On: 12/21/2018 7:58:53 PM
Post# of 72447
Well it's been over four years since B-ABSSSI blew away Daptomycin in phase 2b. The company opted to "maximize" shareholder value by holding off on pursuing a partnership on that in favor of pursuing additional phase 2 trials.. Thus far that strategy has maximized our outstanding share count and minimized most of our portfolios (at least the IPIX portion).
I don't know if it can be categorized as wildly successful - I think that would have entailed a BTD being granted. We simply were given collaborative guidance and permission to proceed to phase 3 - successful but nothing wild about it.
I'd love to see that partnership before the end of the year. So would the market.
True. You'll also be broke along with the rest of us.
I don't know if it can be categorized as wildly successful - I think that would have entailed a BTD being granted. We simply were given collaborative guidance and permission to proceed to phase 3 - successful but nothing wild about it.
I'd love to see that partnership before the end of the year. So would the market.
Quote:
If we don't get a deal forthwith I will be more than shocked and dismayed.
True. You'll also be broke along with the rest of us.
(1)
(1)
